Group 1 - The company, BeiGene, stated that its investment in Wuhan Heyuan Biotechnology Co., Ltd. is accounted for under other equity instruments, and the fair value changes are recorded in other comprehensive income, which does not affect the company's net profit [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 (万元) | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | | | | 2026-01-21 | 300558 | 贝达药业 | 38.62 | 12.68 | 489.70 中信建投证券股份 | 中信建投证券股份 | | | | | | | 有限公司北京朝阳 | 有限公司北京朝阳 | | | | | | | 分公司 | 分公司 | 1月21日，贝达药业大宗交易成交12.68万股，成交额489.7万元，占当日总成交额的1.81%，成交价38.62 元，较市场收盘价48.77元折价20.81%。 ...

Group 1 - The company, Betta Pharmaceuticals (300558.SZ), announced a commercial cooperation with Wuhan Heyuan Biotechnology Co., Ltd. for the regional commercialization of recombinant human albumin injection (rice-based) [1] - The recombinant human albumin product is considered breakthrough, with clinical research showing efficacy comparable to human plasma albumin while overcoming safety risks associated with blood sources [1] - The company holds a 5.6% stake in Heyuan Biotechnology, which is currently under a lock-up period lasting one year post-IPO [1]

Group 1 - The core viewpoint of the article is that Betta Pharmaceuticals is actively progressing with multiple clinical studies for MCLA-129 and will announce any significant developments in a timely manner [2] Group 2 - An investor inquired about the timeline for the removal of MCLA-129 from the pipeline and the calculation of losses associated with it [2] - Betta Pharmaceuticals responded that the clinical research for MCLA-129 is ongoing and organized [2]

Core Viewpoint - The company is strategically planning to advance the domestic clinical research and market application of EYP-1901 based on international clinical progress and domestic commercialization plans [1] Group 1: Clinical Development - The company's partner, EYEPOINT, has completed enrollment for two Phase III clinical trials for the wAMD indication in 2025 [1] - The first patient enrollment for the Phase III clinical trial for the DME indication is planned for the first quarter of 2026, with clinical work progressing smoothly [1]

Core Viewpoint - Bidafarma has invested in Hanshi Aitai, becoming one of its significant shareholders, and is inquiring about the innovative directions and achievements of Hanshi Aitai, as well as potential collaborations in technology and sales [1] Group 1: Company Overview - Hanshi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. is an innovative biotech company focused on structural biology, translational medicine, and clinical development [1] - The company has established a product pipeline centered on self-innovated drugs targeting tumors and immune diseases [1] Group 2: Technological Innovations - Hanshi Aitai has developed a globally patented high-affinity, long half-life antibody screening platform [1] - The company has also created an innovative technology platform for tumor-targeted Geographical Positioning Small molecule-Antibody (GPSmAb) [1] Group 3: Shareholding and Future Collaborations - Bidafarma currently holds a 4.72% stake in Hanshi Aitai [1] - Any significant future collaborations will be disclosed in accordance with legal regulations [1]

针对上述提问，贝达药业回应称："您好！公司港股上市发行相关工作正有序推进中，如有下一步重大 进展将及时公告披露。公司一贯重视与合作伙伴的协作关系，目前双方已就里程碑付款进行相关的沟通 和交流，会妥善解决。谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向贝达药业提问："你好董秘 市场有传言因为益方生物应付款问题，公司遭到港交 所问询，被驳回上市请求。请董秘辟谣，或予以证实。" 本文源自：市场资讯 作者：公告君 ...

证券日报网讯 1月15日，贝达药业在互动平台回答投资者提问时表示，公司通过自主研发或与领先的第 三方AI平台合作，将人工智能应用于靶点发现和评估、耐药机制识别及真实世界数据的机器学习等， 从而赋能早期药物研发与临床研究，助力提升研发效率。 （文章来源：证券日报） ...

Core Viewpoint - Beida Pharmaceutical is investing in Hangzhou Zhixing Pharmaceutical Co., Ltd. to enhance its capabilities in high-end inhalation formulations, aligning with its long-term development strategy [2] Group 1: Company Strategy - The investment in Zhixing Pharmaceutical focuses on high-end inhalation formulation research and production, which is a strategic move for Beida Pharmaceutical [2] - The collaboration between Beida Pharmaceutical and Zhixing Pharmaceutical will involve deep cooperation in innovative research and technology platforms [2] Group 2: Industry Development - Zhixing Pharmaceutical has a strong industry background among its core technical personnel and has established a comprehensive research and production system [2] - The partnership is expected to expand Beida Pharmaceutical's new drug creation technology platform and broaden its strategic layout in disease treatment areas [2]

Core Insights - Bidda Pharmaceutical has signed a strategic cooperation agreement with Westlake University to focus on life sciences and pharmaceutical innovation, emphasizing student training, technological breakthroughs, platform construction, and achievement transformation [1][2] - The collaboration aims to enhance the entire chain from basic research to industrial application, reflecting the growing innovation environment in Hangzhou [1] Group 1: Company Initiatives - Bidda Pharmaceutical is a leading domestic innovative drug company that has established four funds to incubate nearly 30 cutting-edge projects across various fields, including small molecules, antibodies, gene/cell therapy, and CDMO [1] - The "Bidda Innovation Ecosystem Alliance" was established at the ninth Wanwu Growth Conference, aiming to integrate resources from industry, academia, research, healthcare, and investment to enhance collaborative efficiency [1] Group 2: Project Developments - The RGB-5088 pancreatic cell injection project, part of the ecosystem, received approval from the National Medical Products Administration to enter clinical trials on December 6, 2024, showcasing the ecosystem's ability to accelerate early-stage original projects [1] Group 3: Industry Environment - Hangzhou has implemented numerous supportive policies for innovative drugs and medical devices, creating a conducive environment for entrepreneurship and innovation [1] - The Yangtze River Delta Biopharmaceutical Industry Development Conference held in December last year fostered a consensus on collaboration among capital, technology, and industry, providing a broad platform for university-enterprise cooperation and achievement transformation [1]